Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Wells

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
European Journal of Pharmacology|October 24, 2009
Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat modelStephan Grant, Phong Tran, Qin Zhang, et al.
The Lancet. Oncology|February 14, 2022
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trialDean A Fennell, Amy King, Seid Mohammed, et al.
Molecular Cancer Therapeutics|June 15, 2014
Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancerPei-Pei Kung, Ricardo Martinez, Zhou Zhu, et al.
The Lancet. Oncology|October 17, 2021
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trialDean A Fennell, Sean Ewings, Christian Ottensmeier, et al.
Journal of Medicinal Chemistry|August 12, 2016
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) InhibitorsPei-Pei Kung, Eugene Rui, Simon Bergqvist, et al.
Journal of Medicinal Chemistry|December 13, 2016
Correction to Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) InhibitorsPei-Pei Kung, Eugene Rui, Simon Bergqvist, et al.
Nature Communications|June 8, 2021
Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironmentMin Zhang, Jin-Li Luo, Qianqian Sun, et al.
Nature Communications|March 20, 2021
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironmentMin Zhang, Jin-Li Luo, Qianqian Sun, et al.
Faraday Discussions|June 22, 2016
Designing new catalysts: synthesis of new active structures: general discussionParasuraman Selvam, Joachim Sauer, Bruce Garrett, et al.
Nature Communications|July 21, 2025
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trialDean A Fennell, Kayleigh Hill, Min Zhang, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
European Journal of Pharmacology|October 24, 2009
Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat modelStephan Grant, Phong Tran, Qin Zhang, et al.
The Lancet. Oncology|February 14, 2022
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trialDean A Fennell, Amy King, Seid Mohammed, et al.
Molecular Cancer Therapeutics|June 15, 2014
Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancerPei-Pei Kung, Ricardo Martinez, Zhou Zhu, et al.
The Lancet. Oncology|October 17, 2021
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trialDean A Fennell, Sean Ewings, Christian Ottensmeier, et al.
Journal of Medicinal Chemistry|August 12, 2016
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) InhibitorsPei-Pei Kung, Eugene Rui, Simon Bergqvist, et al.
Journal of Medicinal Chemistry|December 13, 2016
Correction to Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) InhibitorsPei-Pei Kung, Eugene Rui, Simon Bergqvist, et al.
Nature Communications|June 8, 2021
Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironmentMin Zhang, Jin-Li Luo, Qianqian Sun, et al.
Nature Communications|March 20, 2021
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironmentMin Zhang, Jin-Li Luo, Qianqian Sun, et al.
Faraday Discussions|June 22, 2016
Designing new catalysts: synthesis of new active structures: general discussionParasuraman Selvam, Joachim Sauer, Bruce Garrett, et al.
Nature Communications|July 21, 2025
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trialDean A Fennell, Kayleigh Hill, Min Zhang, et al.
Pageof 4